JP2005512962A - 抗pdgf抗体および設計抗体の産生方法 - Google Patents

抗pdgf抗体および設計抗体の産生方法 Download PDF

Info

Publication number
JP2005512962A
JP2005512962A JP2003528864A JP2003528864A JP2005512962A JP 2005512962 A JP2005512962 A JP 2005512962A JP 2003528864 A JP2003528864 A JP 2003528864A JP 2003528864 A JP2003528864 A JP 2003528864A JP 2005512962 A JP2005512962 A JP 2005512962A
Authority
JP
Japan
Prior art keywords
antibody
sequence
designed
library
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003528864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512962A5 (cg-RX-API-DMAC7.html
Inventor
キャサリン エス. ボウディッシュ,
シャナ フレデリックソン,
アンキ クレッズ−ロメル,
Original Assignee
アレクシオン ファーマシューティカルズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ, インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ, インコーポレイテッド
Publication of JP2005512962A publication Critical patent/JP2005512962A/ja
Publication of JP2005512962A5 publication Critical patent/JP2005512962A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2003528864A 2001-09-20 2002-09-20 抗pdgf抗体および設計抗体の産生方法 Withdrawn JP2005512962A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32354401P 2001-09-20 2001-09-20
US32353701P 2001-09-20 2001-09-20
US37999402P 2002-05-13 2002-05-13
PCT/US2002/030086 WO2003025019A1 (en) 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies

Publications (2)

Publication Number Publication Date
JP2005512962A true JP2005512962A (ja) 2005-05-12
JP2005512962A5 JP2005512962A5 (cg-RX-API-DMAC7.html) 2005-12-22

Family

ID=27406282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003528864A Withdrawn JP2005512962A (ja) 2001-09-20 2002-09-20 抗pdgf抗体および設計抗体の産生方法

Country Status (4)

Country Link
EP (1) EP1436329A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005512962A (cg-RX-API-DMAC7.html)
CA (1) CA2460587A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003025019A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511706A (ja) * 2001-12-03 2005-04-28 アレクシオン ファーマシューティカルズ, インコーポレイテッド ハイブリッド抗体
JP2015522576A (ja) * 2012-06-28 2015-08-06 モレキュラー・パートナーズ・アーゲーMolecular Partners Ag 血小板由来成長因子に結合する設計アンキリンリピートタンパク質
JP2019006732A (ja) * 2017-06-27 2019-01-17 学校法人東京理科大学 Mycタンパク質阻害剤、Mycタンパク質阻害方法、抗神経芽腫剤及びMycタンパク質の過剰発現を伴う疾患の治療方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
AU2003213022A1 (en) * 2002-02-11 2003-09-22 Alexion Pharmaceuticals, Inc. Immunotherapeutics for biodefense
NZ542988A (en) * 2003-04-23 2008-07-31 Medarex Inc Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2009129538A2 (en) * 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ,エルエルシー 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
JO3787B1 (ar) 2012-03-15 2021-01-31 Janssen Biotech Inc أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2014052518A1 (en) 2012-09-27 2014-04-03 Allergan, Inc. Biodegradable drug delivery systems for the sustained release of proteins
CN105188759A (zh) 2013-03-14 2015-12-23 阿勒根公司 持续释放递送的组合物以及在制造过程中稳定蛋白质的方法
SI4374873T1 (sl) 2013-07-12 2026-01-30 Astellas Us Llc Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
AU1454199A (en) * 1997-11-07 1999-05-31 Massachusetts Institute Of Technology Pdgf-mediated microvascular communication and methods of use thereof
WO1999029888A1 (en) * 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511706A (ja) * 2001-12-03 2005-04-28 アレクシオン ファーマシューティカルズ, インコーポレイテッド ハイブリッド抗体
JP2015522576A (ja) * 2012-06-28 2015-08-06 モレキュラー・パートナーズ・アーゲーMolecular Partners Ag 血小板由来成長因子に結合する設計アンキリンリピートタンパク質
JP2019006732A (ja) * 2017-06-27 2019-01-17 学校法人東京理科大学 Mycタンパク質阻害剤、Mycタンパク質阻害方法、抗神経芽腫剤及びMycタンパク質の過剰発現を伴う疾患の治療方法

Also Published As

Publication number Publication date
CA2460587A1 (en) 2003-03-27
WO2003025019A9 (en) 2004-05-06
WO2003025019A8 (en) 2004-04-01
EP1436329A4 (en) 2005-04-27
WO2003025019A1 (en) 2003-03-27
EP1436329A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
US20030219839A1 (en) Anti-PDGF antibodies and methods for producing engineered antibodies
JP6678627B2 (ja) 治療的低密度リポタンパク質関連タンパク質6(lrp6)多価抗体の組成物および使用方法
JP5685274B2 (ja) 結合タンパク質の混合物
JP6216940B2 (ja) ラクダ科動物由来の抗原結合ポリペプチド
EP1436329A1 (en) Anti-pdgf antibodies and methods for producing engineered antibodies
CN105037543B (zh) 治疗性dll4结合蛋白
JP2015524404A (ja) 高度に保存された標的に対するラクダ科動物由来の配列を含む抗体
CN112646032B (zh) 靶向bcma的具有人猴交叉的人源化单克隆抗体
CN102076714A (zh) 结合Aβ(1-42)球聚体的人源化抗体及其应用
JP7624478B2 (ja) 癌治療において壊死を標的とするヒト化抗核抗体
WO2001031065A1 (en) Humanization of non-human, mammalian antibodies
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
US20060024666A1 (en) Humanized antibodies against the venezuelan equine encephalitis virus
US20150218287A1 (en) Tumor selective antibodies specific to oncofetal antigen/immature laminin receptor protein
CN111201239A (zh) 用于开发特异于表位翻译后修饰状态的抗体的方法和组合物
JP2026509245A (ja) 抗体およびその使用
Padoa et al. Engineered antibodies: A new tool for use in diabetes research
AU2002341785A1 (en) Anti-PDGF antibodies and methods for producing engineered antibodies
CN115244079B (zh) 结合人ngf的抗体、其制备方法和用途
EP4482860A1 (en) Human-like target-binding proteins
Putelli Human antibody phage technology-isolation and characterization of monoclonal antibodies for the targeting of cancer and rheumatoid arthritis
HK1201280B (en) Anti-vegf antibody
HK1201280A1 (en) Anti-vegf antibody

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20060110